Effect of Pretreatment With Ticagrelor on Residual Thrombus After PCI in Patients Presenting With ACS in Comparison With Delayed Treatment at the Time of PCI: an OCT Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01916902 |
Recruitment Status
:
Withdrawn
(Despite a large number of patients screened, very few met eligibility guidelines.)
First Posted
: August 6, 2013
Last Update Posted
: May 26, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Acute Coronary Syndrome Coronary Artery Disease | Drug: Ticagrelor- Delayed Administration Drug: Ticagrelor- Immediate Administration Procedure: Optical Coherence Tomography | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Official Title: | Effect of Pretreatment With Ticagrelor on Residual Thrombus After Percutaneous Coronary Intervention (PCI) in Patients Presenting With Acute Coronary Syndrome in Comparison With Delayed Treatment at the Time of PCI: an Optical Coherence Tomography Study |
Study Start Date : | February 2014 |
Estimated Primary Completion Date : | February 2015 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Ticagrelor- Delayed Administration
Subjects receive 180 mg of ticagrelor during cardiac catheterization after diagnostic angiography and prior to stenting. OCT is performed prior to and after coronary artery stenting.
|
Drug: Ticagrelor- Delayed Administration
Subjects are randomized to receive ticagrelor immediately after enrollment versus at the time of cardiac catheterization. OCT is performed prior to and after coronary artery stenting.
Procedure: Optical Coherence Tomography
|
Active Comparator: Ticagrelor- Immediate Administration
Subjects receive 180 mg of ticagrelor immediately after study enrollment. OCT is performed prior to and after coronary artery stenting.
|
Drug: Ticagrelor- Immediate Administration
Subjects are randomized to receive ticagrelor immediately after enrollment versus at the time of cardiac catheterization. OCT is performed prior to and after coronary artery stenting.
Procedure: Optical Coherence Tomography
|
- Total thrombus burden as measured by the volume of in-stent thrombus quantified by planimetry. [ Time Frame: Thrombus burden will be measured at the end of the coronary artery stenting procedure. ]The total thrombus burden measured on OCT images will be assessed. The volume of in-stent thrombus will be quantified by planimetry.
- PRI (platelet reactivity index) as measured bu the PLT-VASP assay. [ Time Frame: PRI iwill be measured at the time of OCT image acquisition. ]The extent of platelet inhibition will be measured by PLT-VASP and VerifyNow P2Y12 assays.
- P2Y12 Reaction Units as measured by the VerifyNow P2Y12 assay. [ Time Frame: P2Y12 will be measured at the time of OCT image acquisition. ]The extent of platelet inhibition will be measured by PLT-VASP and VerifyNow P2Y12 assays.
- PCI-related myocardial infarction (MI) [ Time Frame: PCI-related MI will be assesed within 24 hours after the end of the coronary artery stenting procedure. ]PCI related myocardial infarction is defined by the third Universal definition of myocardial infarction.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 79 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patient Characteristics:
- Males and non-pregnant females > or equal to 18 and < or equal to 79 years of age presenting with suspected acute coronary syndrome (unstable angina or NSTEMI)
- Patients likely to be scheduled to undergo coronary angiography with possible percutaneous coronary intervention (PCI)
Lesion Characteristics on Diagnostic Coronary Angiography:
- De novo lesions in native coronary arteries found by diagnostic coronary angiography
- Angiographic stenosis <100%
- Reference vessel diameter 2.5 mm - 4.0 mm by visual estimation
Exclusion Criteria:
Patient Specific Exclusion Criteria:
- Subjects who are unable or unwilling to sign the informed consent form.
- Subjects being treated with anti-platelet medications other than aspirin prior to diagnostic catheterization including glycoprotein IIb/IIIa inhibitors.
- Subjects with serious co-morbid conditions that in judgment of the investigator preclude inclusion in this study
- Subjects with NYHA class III or IV heart failure or known left ventricular ejection fraction < 30%.
- Subjects with an ST elevation myocardial infarction.
- Subjects with hemodynamic or electrical instability (including shock).
- Subjects diagnosed with severe, non-catheter-related coronary artery spasm.
- Subjects who are or may be pregnant.
- Subjects with known allergies to contrast media.
- Subjects with eGFR < 60 ml/min/1.73m2.
- Subjects currently taking oral anticoagulants with an absolute contraindication to discontinuation of anticoagulation.
- History of TIA or stroke < 6 months.
- History of hemorrhagic stroke.
- Hepatic insufficiency defined as liver cirrhosis, AST/ALT/Alkaline Phosphatase greater than 3 times the upper limit of normal or hyperbilirubinemia.
- Cardiac catheterization scheduled within 4 hours of randomization or more then 72 hours after randomization.
Lesion Specific Exclusion Criteria. These exclusion criteria apply to the target lesion to be imaged by OCT.
- Lesions located in the left main coronary artery
- Lesions that are heavily calcified
- Lesions where OCT cannot be performed due to technical difficulties
- Other lesions that the investigator deems inappropriate for the procedure such as sites with excessive tortuosity or low flow by TIMI grade.
- Lesions in saphenous vein grafts or arterial conduits.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01916902
United States, Massachusetts | |
Massachusetts General Hospital | |
Boston, Massachusetts, United States, 02114 |
Principal Investigator: | Ik-Kyung Jang, MD, PhD | Massachusetts General Hospital |
Responsible Party: | Ik-Kyung Jang, MD, PhD, Professor of Medicine, Massachusetts General Hospital |
ClinicalTrials.gov Identifier: | NCT01916902 History of Changes |
Other Study ID Numbers: |
2013P001322 |
First Posted: | August 6, 2013 Key Record Dates |
Last Update Posted: | May 26, 2014 |
Last Verified: | May 2014 |
Keywords provided by Ik-Kyung Jang, MD, PhD, Massachusetts General Hospital:
Optical Coherence Tomography Ticagrelor |
Additional relevant MeSH terms:
Syndrome Coronary Artery Disease Myocardial Ischemia Coronary Disease Acute Coronary Syndrome Disease Pathologic Processes Heart Diseases Cardiovascular Diseases Arteriosclerosis |
Arterial Occlusive Diseases Vascular Diseases Ticagrelor Purinergic P2Y Receptor Antagonists Purinergic P2 Receptor Antagonists Purinergic Antagonists Purinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs |